Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).

Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
American Journal of Clinical Nutrition (Impact Factor: 6.92). 01/2009; 88(6):1567-75. DOI: 10.3945/ajcn.2008.26205
Source: PubMed

ABSTRACT Some evidence indicates that a low selenium intake may be associated with an increased risk of prostate cancer.
The aim of this study was to investigate the association of plasma selenium concentration with subsequent prostate cancer risk and to examine this association by stage and grade of disease and other factors.
A nested case-control study was performed among men in the European Prospective Investigation into Cancer and Nutrition (EPIC). The association between plasma selenium concentration and prostate cancer risk was assessed in 959 men with incident prostate cancer and 1059 matched controls.
Overall, plasma selenium concentration was not associated with prostate cancer risk; the multivariate relative risk for men in the highest fifth of selenium concentration compared with the lowest fifth was 0.96 (95% CI: 0.70, 1.31; P for trend = 0.25). There were no significant differences in the association of plasma selenium with risk when analyzed by stage or grade of disease. Similarly, the association of selenium with risk did not differ by smoking status or by plasma alpha- or gamma-tocopherol concentration.
Plasma selenium concentration was not associated with prostate cancer risk in this large cohort of European men.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Within the aim of advancing precision oncology, we have generated a collection of patient-derived xenografts (PDX) characterized at the molecular level, and a pre-clinical model of colon cancer metastasis to evaluate drug-response and tumor progression. Experimental design: We derived cells from 32 primary colorectal carcinomas and eight liver metastases and generated PDX annotated for their clinical data, gene expression, mutational and histopathological traits. Six models were injected orthotopically into the cecum wall of NOD-SCID mice. Three of them were treated with chemotherapy (oxaliplatin) and three with API2 to target AKT activity. Tumor growth and metastasis progression were analyzed by Positron Emission Tomography (PET). Patient-derived cells generated tumor xenografts that recapitulated the same histopathological and genetic features as the original patients carcinomas. We show an 87.5% tumor take rate that is one of the highest described for implanted cells derived from colorectal cancer patients. Cecal injection generated primary carcinomas and distant metastases. Oxaliplatin treatment prevented metastasis and API2 reduced tumor growth as evaluated by PET. Our improved protocol for cancer cell engraftment has allowed us to build a rapidly expanding collection of colorectal PDX, annotated for their clinical data, gene expression, mutational and histopathological statuses. We have also established a mouse model for metastatic colon cancer with patient-derived cells in order to monitor tumor growth, metastasis evolution and response to treatment by PET. Our PDX models could become the best pre-clinical approach through which to validate new biomarkers or investigate the metastatic potential and drug-response of individual patients.
    Clinical Cancer Research 10/2013; 19(24). DOI:10.1158/1078-0432.CCR-12-1740 · 8.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The essential trace element selenium has been shown to have cancer preventive potential by a converging body of epidemiologic and preclinical studies. Although randomized controlled trials suggest a benefit against liver cancer, results at other sites are not as consistent. The Nutritional Prevention of Cancer Trial provided evidence that selenium-enriched yeast can protect against total cancer incidence and the incidence of prostate, lung, and colorectal cancer. In contrast, in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenomethionine provided no protection against prostate, lung, or colorectal cancer. Results from these trials suggest that the cancer protective effects of selenium probably depend on the baseline selenium status of the individual, chemical form of selenium utilized, gender, and genetic polymorphisms in selenoproteins or in cancer-related processes.
    03/2012; 1(1). DOI:10.1007/s13668-011-0003-x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is a systematic review of existing data on dietary selenium (Se) intake and status for various population groups in Europe (including the United Kingdom (UK)) and the Middle East. It includes English language systematic reviews, meta-analyses, randomised controlled trials, cohort studies, cross-sectional and case-control studies obtained through PUBMED searches from January, 2002, to November, 2014, for European data and from 1990 to November 2014, for Middle Eastern data. Reports were selected if they included data on Se intake and status. The search identified 19 European/UK studies and 15 investigations in the Middle East that reported Se intake and Se concentration in water and/or food and 48 European/UK studies and 44 investigations in the Middle East reporting Se status. Suboptimal Se status was reported to be widespread throughout Europe, the UK and the Middle East, and these results agreed with previous reports highlighting the problem. Eastern European countries had lower Se intake than Western European countries. Middle Eastern studies provided varying results, possibly due to varying food habits and imports in different regions and within differing socioeconomic groups. In conclusion, Se intake and status is suboptimal in European and Middle Eastern countries, with less consistency in the Middle East.
    Nutrients 03/2015; 7(3):1494-1537. DOI:10.3390/nu7031494 · 3.15 Impact Factor

Full-text (2 Sources)

Available from
Jun 2, 2014

Similar Publications